The ‘blue’ club plans to convince Barca’s Gabonese striker with a significant improvement from his record
Chelsea are convinced of the suitability of signing Pierre-Emerick Aubameyang. The ‘blue’ club, left without specific attackers after the departure at this summer market from Romelu Lukaku to Inter Milan and Timo Werner to Leipzig, has set the target of the Gabonese striker from Barca, whose priority option is to continue in Camp Well despite stiff competition from Lewandowski.
To counter this player’s initial intent, Stamford Bridge’s bet is to provide him with a significant raise from his record as a Barça player. Thus, this Thursday saw the first meeting between the leaders of Chelsea and the footballer and his representative, with the aim of discussing the conditions in terms of salary and duration, the previous step of handing over a formal offer to Barça.
This ‘blue’ interest has a lot to do with the link between Aubameyang and Chelsea manager Thomas Tuchel, who already met at Borussia Dortmund in the 2015-16 and 2016-17 seasons. Coincidentally, those two campaigns were the best in the striker’s career, scoring 39 goals in the first and 40 in the second, dazzling Europe and leaving an indelible memory on the coach.
“I really enjoyed working with him. It was a pleasure. This has nothing to do with the current situation, but some players are still your players over the years. There was immediately a great bond. We have a very close relationship,” the German coach said a few days ago, questioned about the interest in Aubameyang.
At Barca they initially have the Gabonese as a substitute for Lewandowski, but with Memphis Depay’s departure to Juventus pending confirmation, an interesting proposal from Chelsea could change the established Barca plan.
Source: La Verdad
I’m an experienced news author and editor based in New York City. I specialize in covering healthcare news stories for Today Times Live, helping to keep readers informed on the latest developments related to the industry. I have a deep understanding of medical topics, including emerging treatments and drugs, the changing laws that regulate healthcare providers, and other matters that affect public health.
